DENVER, Colo., Oct 11, 2023 (www.247marketnews.com)- Tempest Therapeutics, Inc. (NASDAQ: TPST) stated, after yesterday’s market close, that it plans to report new and updated data from the global randomized Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) this morning, in a premarket press release, followed by a webcasted conference call with associated slide presentation at 8:30 a.m. EDT.
Tempest Therapeutics is trading at $0.9701, up $0.7302 (+304.38%), on 13.8M premarket shares traded.
Its 52-week range is $0.17 to $4.2144. This move is a massive trend reversal from yesterday’s 52-week low and if the report catches some shorts off guard, it may have some more room to run.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
